New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information
QTRX 10.28.2024
LucentADTMComplete improves on single biomarker tests, significantly reducing the intermediate zone, providing results for more patients
Recent Alzheimer’s Association criteriafor diagnosing Alzheimer’s recommend that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without amyloid pathology, a hallmark of AD. However, this approach leaves an “intermediate zone” of uncertainty, requiring patients that fall into this zone follow up with cerebral spinal fluid measurement via invasive lumbar puncture or costly amyloid PET scans. LucentAD Complete addresses this by reducing the number of patients that fall into the intermediate zone by threefold. The test uses a proprietary algorithm to score five AD-related biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP) providing significantly better amyloid classification compared to single-marker tests alone.
“In over 1,000 patients across three independent clinical cohorts, we achieved guideline performance standard for a blood-based Alzheimer’s diagnostic test, while significantly increasing conclusive results for more patients versus p-Tau 217 alone,” said
The test developmentwas fundedby theAlzheimer’s
“Alzheimer’s is a multifaceted disease and as such, we will need a multi biomarker approach to detect the various underlying pathologies. Multiplex platforms, like Quanterix’s Simoa platform, offer the potential to move us closer to a precision medicine approach,” said
Healthcare providers interested in learning more about
For more information about Quanterix’s work in neurology, visit:https://www.quanterix.com/therapeutic-areas/neurology/.
The Lucent Diagnostics’ tests have been developed and validated by
About
About
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease.
View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241028154403/en/
Media:
Source: